


Edited by
R. E. Babine and S. S. Abdel-Meguid

 WILEY-VCH

Protein Crystallography in Drug Discovery



Volume 20

Series Editors:
R. Mannhold,
H. Kubinyi,
G. Folkers



Series Editors:

Prof. Dr. Raimund Mannhold

Biomedical Research Center
Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstraße 1
40225 Düsseldorf
Germany
raimund.mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

BASF AG Ludwigshafen
c/o Donnersbergstraße 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Department of Applied Biosciences
ETH Zürich
Winterthurerstr. 190
8057 Zürich
Switzerland
folkers@pharma.anbi.ethz.ch

Volume Editors:

Dr. Robert E. Babine

Suntory Pharmaceutical Research Laboratories
One Kendall Square
Cambridge, MA 02139
USA
robert.babine@sprlus.com

Dr. Sherin S. Abdel-Meguid

Suntory Pharmaceutical Research Laboratories
One Kendall Square
Cambridge, MA 02139
USA
sherin.s.abdel-meduid@sprlus.com

This book was carefully produced. Nevertheless, authors, editors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

The cover illustration shows the antidiabetic compound rosiglitazone bound to the nuclear receptor PPAR- γ (see chapter 1).

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published

by Die Deutsche Bibliothek

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <<http://dnb.ddb.de>>

© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany
Printed on acid-free paper

Composition K+V Fotosatz GmbH, Beerfelden

Printing betz-druck gmbh, Darmstadt

Bookbinding Litges & Dopf Buchbinderei GmbH, Heppenheim

ISBN 3-527-30678-1

**Protein Crystallography
in Drug Discovery**

Edited by

R. E. Babine and S. S. Abdel-Meguid

Methods and Principles in Medicinal Chemistry

Edited by

R. Mannhold

H. Kubinyi

G. Folkers

Editorial Board

H.-D. Höltje, H. Timmerman, J. Vacca, H. van de Waterbeemd, T. Wieland

Recently published Volumes:

Vol. 12 Drug Targeting

G. Molema, D.K.F. Meijer (eds.)

2001, ISBN 3-527-29989-0

Vol. 13 Pharmacokinetics and Metabolism in Drug Design

D. Smith, D. Walker, H. van de Waterbeemd

2001, ISBN 3-527-30197-6

Vol. 14 Bioinformatics – From Genomes to Drugs

T. Lengauer (ed.)

2001, ISBN 3-527-29988-2

Vol. 15 Drug-Membrane Interactions

J.K. Seydel, M. Wiese

2002, ISBN 3-527-30427-4

Vol. 16 BioNMR in Drug Research

O. Zerbe (ed.)

2002, ISBN 3-527-30465-7

Vol. 17 Quantum Medicinal Chemistry

P. Carloni, F. Alber (eds.)

2003, ISBN 3-527-30456-8

Vol. 18 Drug Bioavailability

H. van de Waterbeemd, H. Lennernäs, P. Artursson (eds.)

2003, ISBN 3-527-30438-X

Vol. 19 Protein-Ligand Interactions

H.-J. Böhm, G. Schneider (eds.)

2003, ISBN 3-527-30521-1

Preface

Among all new technologies in drug research, structure-based ligand design is one of the most powerful approaches. The drugs Captopril, Dorzolamide and Zanamivir, to mention only some prominent examples, resulted from rational design, based on the knowledge and analysis of protein 3D structures. The discovery of some other drugs, e.g. the more recent HIV protease inhibitors Nelfinavir and Amprenavir, was at least supported by protein crystallography studies. Many other drug candidates that resulted from structure-based design are in clinical development.

Whereas some early attempts of structure-based design failed due to inappropriate physicochemical and pharmacokinetic properties of the ligands, modellers are nowadays aware of the pitfalls in ligand design. Large, greasy ligands are avoided, as well as too polar compounds. According to favorable lead and drug properties, defined e.g. by the Lipinski rule of five, ligand design focuses on compounds with relatively low molecular weight, an intermediate lipophilicity range, and a limited number of hydrogen bond donors and acceptors.

In 1997, Klaus Gubernator and Hans-Joachim Böhm edited a volume on structure-based ligand design in this book series. A comprehensive review by Robert Babine, one of the editors of the current book, and Steven Bender, also published in 1997, discussed the design of aspartic, serine, cysteine, and metalloprotease inhibitors, and of immunosuppressants. The present book deals with some other families of important biological targets, e.g. nuclear receptors and kinases. In addition, several other attractive drug targets are reviewed. A special topic, the design of orthogonal protein-ligand pairs, will become important in personalized medicine. The book closes with chapters on recent progress in technologies: protein engineering to promote crystallization, micro-crystallization, and high-throughput crystallography. With its broad perspective, the book provides a state-of-the-art overview on important results and techniques that are relevant for protein 3D structure-based drug design.

The series editors are grateful to Robert Babine and Sherin Abdel-Meguid for their engaged work and to Frank Weinreich, Wiley-VCH, for ongoing support during the preparation of the book. We expect that volume 20 of "Methods and Principles in Medicinal Chemistry" will be another highlight of this successful series, which started only ten years ago.

September 2003

Raimund Mannhold, Düsseldorf
Hugo Kubinyi, Weisenheim am Sand
Gerd Folkers, Zürich

A Personal Foreword

When approached to initiate this book project the initial thoughts were to remember a review published in 1997 [1]. The first memories of that endeavor were quite painful, so the first instinct was to politely turn down the kind offer to initiate this project. On second reflection, researching and preparing the 1997 review was an educational and rewarding experience. Therefore, with the help of a co-editor, the invitation to initiate and complete this endeavor was accepted.

The objective of this book is to provide a forward looking overview of the use of protein crystallography in drug discovery. It has been organized so that the early chapters review and describe some mature and emerging topics that would fall under the 'traditional structure-based design' umbrella, the middle chapters provide focused accounts of specific works, and the final chapters delve into new and fertile areas of research. This book does not attempt to be comprehensive; thus the final lineup of chapters was a compromise between the interests of the editors and the willingness of the authors to contribute a chapter.

The first two chapters review nuclear hormone receptors and protein kinases. Both of these chapters provide an overview of the topic and shed some insight into how small molecule ligands can achieve selectivity between related protein targets. The next two chapters review topics that begin to 'push the limit' on the size of the complexes that can be used in drug design. Both the proteasome and the ribosome are very large biological macromolecules that are the targets for drug discovery. In the ribosome chapter, an important point is made regarding what conclusions are warranted, or not warranted, based upon the resolution of the x-ray diffraction data. The ribosome chapter also introduces the topic and challenges of antibiotic resistance in drug discovery. The next two chapters provide accounts of detailed structure-based design studies aimed at obtaining inhibitors of both cathepsin K and Cdk4. The cathepsin K chapter provides a nice account of the iterative structure-based design process. This work is especially notable for the use of an unexpected crystallographic result to move a project in a novel direction. The Cdk4 chapter also does an excellent job of introducing many computational methods that are used in drug discovery. For those readers interested in protein-based virtual screening of chemical databases, we also recommend the work by Bissantz *et al.* [2] in which they evaluate different docking/scoring combinations. Chapter 7 describes applications of the protease inhibitor ecotin, particularly its

use as a tool to obtain crystals of serine proteases and to study the interactions between serine proteases and their substrates. Chapter 8 reviews work on ‘orthogonal ligand-receptor pairs’ and the impact of crystallography on this area of research. While ‘traditional structure-based design’ uses the structure of a protein-ligand complex as a tool to design modified ligands, the work on ‘orthogonal ligand-receptor pairs’ uses the structure of the complex as a tool to design both modified proteins and modified ligands. This work has applications for deconvoluting some cellular processes and also provides useful tools in the area of chemical genetics. Protein/ligand pairs may also have future applications in gene therapy. Chapters 7 and 8 present examples that use crystallography to design mutant proteins for additional structural studies. Chapter 9 discusses the use of mutant proteins as an entry into obtaining high-resolution crystal structures. In numerous past examples, when a human protein proved difficult to crystallize, a protein from another species such as mouse, rat, or chicken was often used as a surrogate protein. A potential problem with this approach is that the active sites of the human and the surrogate enzyme might be different. The chapter on “Engineering Proteins to Promote Crystallization” reviews examples where the surface of a human protein is modified in a location remote from the active site to produce a mutant human protein that can give useful crystals. The next chapter discusses “High-throughput crystallography” which is an area of intense interest [3, 4]. This chapter provides a clear overview of the field, and has an informative section on crystallography in lead discovery. The final chapter describes miniaturization of crystallization utilizing the emergent technologies of microfluidics. This technology allows crystallization experiments to be performed on the nanoliter scale, thus conserving a very valuable resource in crystallography, the protein. Many of the technologies described in the final three chapters should impact crystallization and structure determination of the many new proteins identified in the human and other genomes.

We expect that this book will be a useful reference to practitioners of structure-based design. In addition, we hope that the technologies discussed in the later chapters will help researchers solve new problems in the next generation of structure-based design problems.

Cambridge, MA, April 2003

Robert E. Babine
Sherin S. Abdel-Meguid

- 1 BABINE, R. E. and S. L. BENDER, Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. *Chem. Rev.* **1997**, 97(5), 1359–1472.
- 2 BISSANTZ, C., G. FOLKERS, and D. ROGNAN, Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. *J. Med. Chem.* **2000**, 43(25), 4759–4767.
- 3 MOUNTAIN, V., Innovation – Astex, Structural Genomix, and Syrrx. *Chem. Biol.* **2003**, 10, 95–98.
- 4 BERTINI, I., Structural genomics. *Acc. Chem. Res.* **2003**, 36(3), 155.

List of Contributors

JERRY L. ADAMS
GlaxoSmithKline Pharmaceuticals
Medicinal Chemistry
1250 South Collegeville Road
Collegeville, PA 19426
USA

ROBERT E. BABINE
Suntory Pharmaceutical Research
Laboratories LLC
Structural and Computational
Chemistry
One Kendall Square, Bldg 700
Cambridge MA 02139
USA

JAMES M. BERGER
University of California at Berkeley
Department of Molecular
and Cell Biology
229 Stanley Hall
Berkeley, CA 94720-3206
USA

MAXWELL D. CUMMINGS
Computational Chemistry
3-Dimensional Pharmaceuticals
665 Stockton Drive, Suite 104
Exton, PA 19341
USA

DONALD F. DOYLE
Georgia Institute of Technology
School of Chemistry and Biochemistry
770 State Street
Atlanta, GA 30332-0400
USA

ROBERT J. FLETTERICK
Departments of Biochemistry
and Biophysics and Pharmaceutical
Chemistry
University of California
at San Francisco
600 16th Street, Box 2240
San Francisco, CA 94143-2240
USA

CARL L. HANSEN
California Institute of Technology
Department of Applied Physics
MS 128-95
Pasadena, CA 91125
USA

JEFFREY L. HANSEN
Department of Molecular Biophysics
and Biochemistry
Yale University
266 Whitney Avenue, 415 Bass Center
New Haven, CT 06520
USA

TERUKI HONMA
Banyu Tsukuba Research Institute
in collaboration with Merck Research
Laboratories
Okubo-3
Tsukuba 300-2611
Ibaraki
Japan

HARREN JHOTI
Astex Technology Ltd.
250 Cambridge Science Park
Milton Road
Cambridge, CB4 0WE
United Kingdom

LEI JIN
Suntory Pharmaceutical Research
Laboratories LLC
One Kendall Square, Bldg 700
Cambridge MA 02139
USA

TSUNEHIRO MIZUSHIMA
Japan Science and Technology
Corporation
Structure and Function
of Biomolecules
3-18-22 Honkomagome, Bunkyo-ku
Tokyo, 113-0021
Japan

STEPHEN R. QUAKE
California Institute of Technology
Department of Applied Physics
MS 128-95
Pasadena, CA 91125
USA

LAUREN J. SCHWIMMER
Georgia Institute of Technology
School of Chemistry and Biochemistry
770 State Street
Atlanta, GA 30332-0400
USA

KYLE SELF
Fluidigm Corporation
7100 Shoreline Court South
San Francisco, CA 94080
USA

LISA M. SHEWCHUK
GlaxoSmithKline Pharmaceuticals
Discovery Research
5 Moore Drive
Research Triangle Park, NC 27709
USA

MORTEN SOMMER
California Institute of Technology
Department of Applied Physics
MS 128-95
Pasadena, CA 91125
USA

TOMITAKE TSUKIHARA
Institute for Protein Research
Osaka University
3-2, Yamadaoka, Suita
Osaka 565-0871
Japan

JAMES VEAL
Serenex, Inc.
Informatics and Computational
Chemistry
323 Foster St.
Durham, NC 27701
USA

DANIEL F. VEBER
290 Batleson Rd.
Ambler, PA 19002
USA

SANDRA M. WAUGH
University of California
at San Francisco
Graduate Group in Biophysics
San Francisco, CA 94143-2240
USA

Contents

Preface *XI*

A Personal Foreword *XIII*

List of Contributors *XV*

1	Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes	1
	<i>Robert E. Babine</i>	
1.1	Introduction	1
1.1.1	Nuclear Hormone Receptors: Ligand Binding Domains	1
1.1.2	Dimerization and Interactions with Co-activators and Co-repressors	2
1.2	Steroid Receptors	5
1.2.1	The Role of the Ligand	5
1.2.1.1	Estradiol Estrogen Receptor Complex	5
1.2.1.2	Other Estrogen Receptor Agonists Complexes	8
1.2.1.3	Estrogen Receptor Antagonists Complexes	9
1.2.1.4	Genistein – An ER- β Partial Agonist	12
1.2.1.5	<i>R,R-5,11-cis-Diethyl-5,6,11,12-tetrahydrochrysen-2,8-diol</i> : An ER- α Agonist and ER- β Antagonist	14
1.2.2	Structural Basis for Agonism and Antagonism and Partial Agonism: The Role of the Ligand	15
1.2.3	Progesterone/Progesterone Receptor Complex	16
1.2.4	Androgen Receptor Complexes	17
1.2.5	Glucocorticoid Receptor	18
1.2.6	Steroid Ligand Selectivity	19
1.3	The Vitamin D Receptor-Ligand Complexes	22
1.4	The Retinoic Acid Receptors RAR and RXR	23
1.4.1	Introduction	23
1.4.2	RAR- γ and RXR- α Retinoid Complexes	25
1.4.3	Selectivity of RAR Ligands and RAR Isoforms	27
1.4.4	RXR Complexes with Unnatural Ligands	33
1.5	PPAR: Isoform-Selective Ligands	34
1.6	Summary	41
1.7	Acknowledgements	43

1.8	References	43
2	Kinases	<i>47</i>
	<i>Jerry L. Adams, James Veal, and Lisa Shewchuk</i>	
2.1	Introduction	47
2.2	Structure and Function	48
2.2.1	Tertiary Structure	48
2.2.2	Catalysis and Substrate Binding	49
2.2.3	Regulation and Conformational Flexibility	50
2.2.3.1	Activation Loop Conformation	50
2.2.3.2	Glycine Rich Loop	51
2.2.3.3	C-Helix Orientation	51
2.2.3.4	Lobe Orientation	53
2.2.3.5	Solvent Channel	53
2.3	Crystallization	54
2.3.1	Defining the Construct	54
2.3.2	Mutagenesis	55
2.3.3	Phosphorylation	55
2.4	Inhibitor Design	56
2.4.1	Binding in ATP Cleft	56
2.4.1.1	ATP Binding Sites	57
2.4.1.2	Gatekeeper-Dependent Binding Pocket	60
2.4.1.3	Lipophilic Plug	61
2.4.1.4	Polar Surface Site	61
2.4.2	Conformational Considerations	63
2.4.2.1	Inhibitor-Induced Binding	63
2.4.2.2	What is the Most Appropriate Enzyme Form for Crystallography?	64
2.4.2.3	Homology Models and Surrogate Kinases	66
2.4.3	Paradigms for Kinase Drug Discovery	68
2.4.3.1	High Throughput Screening	68
2.4.3.2	Structure-Based Design	69
2.4.3.3	Mechanism-Based and Ligand Mimetic Design	72
2.4.3.4	Computational Chemistry and Virtual Screening	72
2.4.4	Selectivity	73
2.5	Conclusion	75
2.6	References	76
3	The Proteasome as a Drug Target	83
	<i>Tsunehiro Mizushima and Tomitake Tsukihara</i>	
3.1	Introduction	83
3.2	The Ubiquitin-Proteasome System	83
3.2.1	Role of the Ubiquitin-Proteasome System	84
3.2.2	26S Proteasome	85
3.2.3	20S Proteasome	85
3.3	Structure of the 20S Proteasome	86

- 3.3.1 Active Sites of Eukaryotic 20S Proteasomes 88
- 3.3.2 Novel Ntn-Hydrolase Active Site of the $\beta 7$ Subunit 88
- 3.3.3 Predicted Structure of Immunoproteasome and Substrate Specificities 89
- 3.4 Proteasome Inhibitors 93
- 3.4.1 Structure of Proteasome Inhibitor Complexes 95
- 3.5 Conclusions 96
- 3.6 Acknowledgements 96
- 3.7 References 96

- 4 Antibiotics and the Ribosome 99**
Jeffrey L. Hansen
- 4.1 Introduction 99
- 4.2 The Ribosome 99
- 4.2.1 Introduction 99
- 4.2.2 Binding of tRNA 100
- 4.2.3 Peptidyl Transferase Activity 101
- 4.2.4 Structure of the Ribosome 102
- 4.3 Antibiotics 103
- 4.3.1 Introduction 103
- 4.3.2 Antibiotics that Bind to the 50S Subunit 104
- 4.3.3 MLS_B Antibiotics 105
- 4.3.4 Macrolides 107
- 4.3.4.1 Macrolides, 15- and 16-Membered 107
- 4.3.4.2 Binding Interactions Between the Lactone Ring and the Ribosome 108
- 4.3.4.3 Sugar Interactions with the Ribosome 110
- 4.3.4.4 A Covalent Bond 111
- 4.3.4.5 Macrolides, 14-Membered 112
- 4.3.4.6 Rational Drug Design of Macrolides 112
- 4.3.5 Lincosamides 114
- 4.3.6 Streptogramins 114
- 4.3.7 Chloramphenicol 115
- 4.3.8 Nucleoside Analogue Antibiotics 117
- 4.3.8.1 Puromycin 117
- 4.3.8.2 Aminoacyl-4-aminohexosyl-cytosine Antibiotics 118
- 4.3.9 Other Antibiotics that Bind to the 50S Subunit 119
- 4.3.9.1 Sparsomycin 119
- 4.3.9.2 Anisomycin 120
- 4.4 Prospects for Rational Drug Design of Antibiotics that Bind to the Ribosome 120
- 4.5 Acknowledgements 122
- 4.6 References 122

5	Structure-Based Design of Cathepsin K Inhibitors	127
	<i>Daniel F. Veber and Maxwell D. Cummings</i>	
5.1	Introduction	127
5.2	Background and Issues to be Addressed Using Protein Structure	128
5.3	Cysteine Protease Inhibitors: Historical Perspective	131
5.4	Diaminoketone-Based Inhibitors	133
5.5	Cyclic Diaminoketone Inhibitors	136
5.6	Alkoxymethyl and Thiomethyl Dipeptidyl Ketone-Based Inhibitors	140
5.7	Diacylcarbohydrazides	142
5.8	Conclusions	143
5.9	References	145
6	Structure-Based Design of Potent and Selective Cdk4 Inhibitors	147
	<i>Teruki Honma</i>	
6.1	Introduction	147
6.2	Homology Modeling of Cdk4	148
6.3	Analysis of the ATP Binding Pocket	151
6.4	Strategies for Structure-Based Lead Identification: Virtual Screening of Known Compounds and de Novo Design	152
6.4.1	New de Novo Design Strategies	153
6.4.2	Evaluation of Chemical Availability by SEEDS	155
6.5	Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors	157
6.5.1	Identification of New Scaffold Candidates Using LEGEND and SEEDS	157
6.5.2	From the Identified Scaffold to Lead Compounds	159
6.5.3	Confirmation of the Binding Mode	159
6.6	Structure-Based Design of Cdk4 Selective Inhibitors	160
6.6.1	Identification of Cdk4-Specific Amino Acid Residues	161
6.6.2	Library Design Based on the Locations of Cdk4-Specific Amino Acid Residues	163
6.7	Conclusion	167
6.8	Acknowledgements	167
6.9	References	168
7	Crystallization and Analysis of Serine Proteases with Ecotin	171
	<i>Sandra M. Waugh and Robert J. Fletterick</i>	
7.1	What is Ecotin?	171
7.2	Methods	173
7.2.1	Expression of Wild Type Ecotin	173
7.2.2	Purification of Wild Type Ecotin	174
7.2.3	Crystallization of Ecotin and Protease Complexes	175
7.3	Representative Examples of Ecotin and Protease Structures	175
7.3.1	Ecotin Defines the S7 Through S4' Subsites of Collagenase	176

7.3.2	Ecotin as a Tight Binding Substrate	177
7.3.3	Ecotin Defines Regions Distal to the Factor Xa Protease Domain	178
7.4	Crystallization and Structure Determination of E ₂ P ₂ Complexes	180
7.5	Conclusion	183
7.6	References	184

8 X-ray Crystallography in the Development of Orthogonal Ligand–Receptor Pairs 187

Donald F. Doyle and Lauren J. Schwimmer

8.1	Introduction	187
8.2	Applications of OLRPs	188
8.2.1	Applications in Basic Research	188
8.2.2	Applications in Applied Research	189
8.3	Early Work	189
8.4	Structure-Guided Mutagenesis and OLRPs	190
8.4.1	Binding Pocket Mutations	191
8.4.1.1	Nuclear Receptors	191
8.4.1.2	Estrogen Receptor OLRPs	193
8.4.1.3	Retinoic Acid Receptor OLRPs	195
8.4.1.4	Retinoid X Receptor OLRPs	195
8.4.2	Distant Mutations	197
8.5	Other Examples of OLRPs	200
8.5.1	Chemical Inducers of Dimerization to Control Transcription	200
8.5.2	OLRPs and ATP Analogues	202
8.6	Summary	204
8.7	References	206

9 Engineering Proteins to Promote Crystallization 209

Lei Jin and Robert E. Babine

9.1	Introduction	209
9.2	Removing Protein Heterogeneity by Truncation	210
9.3	Removing Protein Heterogeneity by Point Mutation	211
9.4	Improving Crystal Packing by Point Mutation	212
9.5	Acknowledgements	214
9.6	References	214

10 High-throughput Crystallography 217

Harren Jhoti

10.1	Introduction	217
10.2	Technological Advances	218
10.2.1	Clone to Crystal	218
10.2.1.1	Protein Production	218
10.2.1.2	Crystallization	219
10.2.2	Crystal to Structure	220
10.2.3	Progress in Structural Genomics	221

10.3	High-throughput Crystallography in Lead Discovery	223
10.3.1	Protein-Ligand Crystal Structures	224
10.4	Fragment-Based Lead Discovery	225
10.4.1	Fragment-Based Lead Discovery Using X-ray Crystallography	226
10.4.2	Structure-Based Optimization of Fragment Hits	229
10.5	Conclusions	230
10.6	Acknowledgements	231
10.7	References	231

11 Micro-Crystallization 235
*Carl L. Hansen, Morten Sommer, Kyle Self, James M. Berger,
and Stephen R. Quake*

11.1	Introduction	235
11.2	Microfluidics – Method and Design	237
11.3	Utility of Microfluidics for Crystallization	242
11.4	References	253

Subject Index 257

1

Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes

ROBERT E. BABINE

1.1

Introduction

1.1.1

Nuclear Hormone Receptors: Ligand Binding Domains

Nuclear hormone receptors (NHR) are multidomain proteins that function as transcription factors. They contain a central DNA binding domain (DBD) responsible for targeting the receptor to highly specific DNA sequences comprising a response element. The DBD is surrounded by two activation domains: the activation function 1 (AF-1) domain that resides at the N-terminus and the activation function 2 (AF-2) domain that resides at the C-terminal ligand-binding domain (LBD) [1, 2]. NHRs for which no natural ligand is known are referred to as orphan nuclear hormone receptors. Regulation of gene transcription by nuclear receptors requires the recruitment of proteins characterized as co-regulators, with ligand-dependent exchange of co-repressors for co-activators serving as the basic mechanism for switching gene repression to activation [2]. Upon activation by a small molecule ligand, or hormone, NHRs dimerize with another ligated NHR and recruit co-activators to turn on target genes. The binding of a ligand thus can act as a switch between gene activation and gene repression. This biological property has made the ligand binding domains of nuclear hormone receptors important drug targets.

Our understanding at the molecular level of how nuclear receptor ligands exert their effects has been dramatically enhanced by the elucidation of the crystal structures of the apo- and/or ligand-bound LBDs of several nuclear receptors (Tab. 1.1). These structures have revealed a common fold among LBDs, consisting of an antiparallel α -helical sandwich of 11–13 helices. Conventional nomenclature refers to these helices as helix-1, and helices-3 through 12. The region between helices 1 and 3 is variable and may contain zero, one or two helices. The helices fold to form a hydrophobic cavity into which the ligand can bind. The position of helix-12 relative to the other helices is dependent upon the presence or absence of a ligand and the nature of that ligand. The binding site that comprises the AF-2 domain is determined by the position of the C-terminal α -helix (helix-12).

Tab. 1.1 PDB codes of all nuclear hormone receptor-ligand-binding domains in the protein data bank as of December 2002.

<i>Protein</i>	<i>Apo structure</i>	<i>Ligated structures</i>	<i>Complex dimer structure</i>
ER- α		1A52, 1ERE, 1ERR, 1QKT, 1QKU, 3FRD, 3ERT, 1L2I, 1GWQ, 1GWR	
ER- β		1QKM, 1QKN, 1HJ1, 1L2J	
AR		1I37, 1I38, 1E3G	
GR		1MZZ, 1NHZ	
TR- β		1BSX	
RAR- α			1DKF
RAR- γ		1EXA, 1EXX, 1FCX, 1FCY, 1FCZ, 2LBD, 3LBD, 4LBD, 1FD0	
RXR- α	1G1U, 1LBD	1FBY, 1G5Y, 1MV9, 1MVC, 1MZN	1DKF, 1FM6, 1FM9, 1K74
RXR- β		1H9U	
PR		1A28, 1E3K	
VDR		1DB1, 1IE8, 1IE9	
PPAR- α		1I7G, 1K7L, 1KKQ	
PPAR- γ	1PRG, 3PRG	1I7I, 2PRG, 4PRG, 1KNU	1FM6, 1FM9, 1K74
PPAR- δ	2GWX	1GWX, 3GWX	
PXR	1ILG	1ILH	
ROR- β		1K4W	
ROR- α		1N83	
HNF4- γ		1LV2	
ERR3	1KV6		

ER Estrogen Receptor, AR Androgen Receptor, GR Glucocorticoid Receptor, TR Thyroid Receptor, RAR Retinoic Acid Receptor, RXR Retinoic X Receptor, PR Progesterone Receptor, VDR Vitamin D Receptor, PPAR Peroxisome Proliferator-Activated Receptor, PXR Pregnane X Receptor, ROR Retinoic Acid-Related Orphan Receptor, HNF-4 Hepatocyte Nuclear Factor 4, ERR Estrogen-Related Receptor

1.1.2

Dimerization and Interactions with Co-activators and Co-repressors

The Glaxo group was the first to report the structure of a heterodimeric complex between two activated NHRs (peroxisome proliferator-activated receptor- γ) PPAR- γ and (retinoid X receptor- α) RXR- α . The structure (PDB entry: 1FM6) of this heterodimer complex contains six components: the two receptor LBDs, their two respective ligands, and two peptides derived from the steroid receptor co-activator-1 (SRC-1). These peptides contain a conserved LxxLL motif that is present in this class of co-activators. The complex is butterfly shaped, with both LBDs adopting the conserved “helical sandwich” fold previously reported for other ligand-bound nuclear receptors. PPAR- γ contains 13 α -helices and four short β -strands, while RXR- α is composed of 11 α -helices and two short β -strands [3]. This complex is illustrated in Fig. 1.1.